| Opioid dependence |
| Classification and external resources |
|
| ICD-10 |
F11.2 |
| ICD-9 |
304.0 |
| MeSH |
D009293 |
Opioid dependence is a medical diagnosis characterized by an individual's inability to stop using opiates (morphine, heroin, codeine, oxycodone, hydrocodone, etc.) even when objectively it is in his or her best interest to do so, and is a major component of opioid addiction. In 1964 the WHO Expert Committee on Drug Dependence introduced "dependence" as "A cluster of physiological, behavioural and cognitive phenomena of variable intensity, in which the use of a psychoactive drug (or drugs) takes on a high priority. The necessary descriptive characteristics are preoccupation with a desire to obtain and take the drug and persistent drug-seeking behaviour. Determinants and problematic consequences of drug dependence may be biological, psychological or social, and usually interact". The core concept of the WHO definition of "drug dependence" requires the presence of a strong desire or a sense of compulsion to take the drug; and the WHO and DSM-IV-TR clinical guidelines for a definite diagnosis of "dependence" require that three or more of the following six characteristic features be experienced or exhibited:
- A strong desire or sense of compulsion to take the drug;
- Difficulties in controlling drug-taking behaviour in terms of its onset, termination, or levels of use;
- A physiological withdrawal state when drug use is stopped or reduced, as evidenced by: the characteristic withdrawal syndrome for the substance; or use of the same (or a closely related) substance with the intention of relieving or avoiding withdrawal symptoms;
- Evidence of tolerance, such that increased doses of the drug are required in order to achieve effects originally produced by lower doses;
- Progressive neglect of alternative pleasures or interests because of drug use, increased amount of time necessary to obtain or take the drug or to recover from its effects;
- Persisting with drug use despite clear evidence of overtly harmful consequences, such as harm to the liver, depressive mood states or impairment of cognitive functioning.
The Walid-Robinson Opioid-Dependence (WROD) Questionnaire was designed based on these guidelines. According to position papers on the treatment of opioid dependence published by the United Nations Office on Drugs and Crime and the World Health Organization, care providers should not mistake opioid dependence for a weakness of character or will.[1][2] Accordingly, detoxification alone does not constitute adequate treatment.
|
Contents
- 1 Causes
- 2 Symptoms of withdrawal
- 2.1 Physical symptoms
- 2.2 Psychological symptoms
- 3 Treatment
- 3.1 Methadone
- 3.2 Buprenorphine
- 3.3 Naltrexone
- 3.4 Diamorphine
- 3.5 LAAM
- 3.6 Experimental treatments
- 3.7 12-step support groups
- 4 See also
- 5 References
- 6 External links
|
Causes[edit]
It has been demonstrated that most opioid-dependent patients suffer from at least one severe psychiatric comorbidity.[3] Since opioids used in pain therapy rarely cause any of these conditions, they are assumed to have existed prior to the development of dependence.[citation needed] Opioids are known to have strong antidepressive, anxiolytic and antipsychotic effects and thus opioid dependence often develops as a result of self medication.[citation needed] Opioids are excellent acute pain medication, but it is their ability to produce euphoria that makes them attractive to addicts.[4]
Material used for intravenous injection of opiates
Furthermore some studies suggest a permanent dysregulation of the endogenous opioid receptor system after chronic exposure to opioids. A recent study has shown that an increase in BDNF, brain-derived neurotrophic factor, in the ventral tegmental area (VTA) in rats can cause opiate-naive rats to begin displaying opiate-dependent behavior, including withdrawal and drug-seeking behavior.[5] It has been shown that when an opiate-naive person begins using opiates at levels inducing euphoria, this same increase in BDNF occurs.[6]
Another recent study concluded to have shown "a direct link between morphine abstinence and depressive-like symptoms" and postulates "that serotonin dysfunction represents a main mechanism contributing to mood disorders in opiate abstinence".[7] As of 2008, the gateway drug for the youth in USA became opioid drugs instead of marijuana. This is far more dangerous as opioids are more addictive and there is the possibility of dying by overdose, unlike in the case of cannabis.[8]
Symptoms of withdrawal[edit]
Symptoms of withdrawal from opiates include, but are not limited to,
Physical symptoms[edit]
- Tremors
- Cramps
- Muscle and bone pain
- Chills
- Perspiration (sweating)
- Priapism
- Tachycardia (rapid heart beat)
- Itch
- Restless legs syndrome
- Flu-like symptoms
- Rhinitis (runny, inflamed nose)
- Yawning
- Sneezing
- Vomiting
- Diarrhea
- Weakness
- Akathisia (a profoundly uncomfortable feeling of inner restlessness)
Psychological symptoms[edit]
- Dysphoria
- Malaise
- Cravings
- Anxiety/Panic Attacks
- Paranoia
- Insomnia
- Dizziness
- Nausea
- Depression
Other rare but much more serious symptoms include cardiac arrhythmias, strokes, seizures, dehydration and suicide attempts.
Depending on the quantity, type, frequency, and duration of opioid use, acute physical withdrawal symptoms last for as little as two to seven days (for short-acting opioids such as hydromorphone [Dilaudid] and oxycodone) and as long as seven to ten days for long-acting opioids such as buprenorphine and methadone. This initial withdrawal is characterized by the body attempting to regain homeostasis as a result of the brain's lack of opioid receptor activity. Since the mechanisms of opioid dependence and withdrawal are not fully understood, it is difficult to determine how long withdrawal symptoms will last or how severe they may be for different individuals.
Treatment[edit]
Opioid dependence is a complex health condition that often requires long-term treatment and care. The treatment of opioid dependence is important to reduce its health and social consequences and to improve the well-being and social functioning of people affected. The main objectives of treating and rehabilitating persons with opioid dependence are to reduce dependence on illicit drugs; to reduce the morbidity and mortality caused by the use of illicit opioids, or associated with their use, such as infectious diseases; to improve physical and psychological health; to reduce criminal behaviour; to facilitate reintegration into the workforce and education system and to improve social functioning. The ultimate achievement of a drug free state is the ideal and ultimate objective but this is unfortunately not feasible for all individuals with opioid dependence, especially in the short term.
As no single treatment is effective for all individuals with opioid dependence, diverse treatment options are needed, including psychosocial approaches and pharmacological treatment.[9]
Relapse following detoxification alone is extremely common, and therefore detoxification rarely constitutes an adequate treatment of substance dependence on its own. However, it is a first step for many forms of longer-term abstinence-based treatment. Both detoxification with subsequent abstinence-oriented treatment and substitution maintenance treatment are essential components of an effective treatment system for people with opioid dependence.[10]
Current trends in the US reveal a significant increase of prescription opioid abuse compared to illicit opiates such as heroin. This development has also implications for the prevention, treatment and therapy of opioid dependence.[11]
Methadone[edit]
Main article: Methadone maintenance
MMT (Methadone Maintenance Treatment), a form of opioid replacement therapy, reduces and/or eliminates the use of illicit opiates, the criminality associated with opiate use, and allows patients to improve their health and social productivity.[12][13] In addition, enrollment in methadone maintenance has the potential to reduce the transmission of infectious diseases associated with opiate injection, such as hepatitis and HIV.[12] The principal effects of methadone maintenance are to relieve narcotic craving, suppress the abstinence syndrome, and block the euphoric effects associated with opiates. Methadone maintenance has been found to be medically safe and non-sedating.[12] It is also indicated for pregnant women addicted to opiates.[12] Methadone maintenance Treatment is given to addicted individuals who feel unable to go the whole way and get clean. For those individuals who wish to completely move away from drugs, a methadone reduction program is indicated, where the individual is prescribed an amount of methadone which is titrated up until withdrawal symptoms subside, followed by a period of stability, the dose will then be gradually reduced until the individual is either free of the need for methadone or is at a level which allows a switch to a different opiate with an easier withdrawal profile, such a Suboxone.[14]
Buprenorphine[edit]
Main article: Buprenorphine
Studies have shown buprenorphine to be a safer alternative over methadone in opiate replacement therapy, primarily due to its lower instance of overdose related deaths during the course of treatment.[15] Buprenorphine sublingual preparations are often used in the management of opioid dependence (that is, dependence on heroin, oxycodone, hydrocodone, morphine, oxymorphone, fentanyl or other opioids). The Suboxone and Subutex preparations were approved for this indication by the United States Food and Drug Administration in October 2002. This was only possible due to the Drug Addiction Treatment Act of 2000 which overturned a series of 1914–1920 Supreme Court rulings that had found that maintenance and detox treatments were not a form of medical treatment.[citation needed] Although the rulings had the power of legal precedent prior to 2000, it is likely that they were not the intended interpretation of the laws passed originally by congress.[citation needed]
Naltrexone[edit]
Main article: Naltrexone
Naltrexone was approved by the FDA in 1984 for the treatment of opioid dependence. It is available both as an oral medication and as a monthly injectable (approved in 2010). Some authors question whether oral Naltrexone is as effective in the treatment of opioid dependence as methadone and buprenorphine mainly due to non-compliance.[16] The monthly injectable naltrexone preparations have been designed to overcome the problems of compliance encountered with the oral formulation.
Diamorphine[edit]
See also: Heroin maintenance
In Switzerland, Germany, the Netherlands, and the United Kingdom, longterm injecting drug users who do not benefit from methadone and other medication options are being treated with pure injectable diamorphine that is administered under the supervision of medical staff. For this group of patients, diamorphine treatment has proven superior in improving their social and health situation.[17] Studies show that even after years of homelessness and delinquency and despite severe comorbidities, about half of the patients find employment within the first year of treatment.[18]
LAAM[edit]
See also: Levacetylmethadol
LAAM was previously used to treat opioid dependence. In 2003 the drug's manufacturer discontinued production. At this time there are no available generic versions produced.
Experimental treatments[edit]
- Clonidine[19][20]
- Dextromethorphan[21]
- Ibogaine[22]
- Ketamine[21]
- Medical cannabis[23][24]
- Mitragynine[25]
- Tramadol[26][27]
12-step support groups[edit]
Main article: Twelve-step program
While medical treatment may help with the initial symptoms of opioid withdrawal, once an opiate addict overcomes the first stages of withdrawal, a method for long-term preventative care is attendance at 12-step groups such as Alcoholics Anonymous or Narcotics Anonymous. Attendance and participation in a 12 step program is an effective way to obtain and maintain sobriety.[28] Among primarily inner city minorities who had a "long severe history of (primarily) crack and/or heroin use", 51.7% of the individuals with continuous 12-step attendance had over 3 years of sustained abstinence, in contrast to 13.5% among those who had less than continuous 12-step attendance.[29][30]
See also[edit]
- Opioids
- Opioid receptor
- Opioid replacement therapy
- Benzodiazepine withdrawal syndrome
- Physical dependence
- Doctor shopping
- Prescription drug abuse
References[edit]
- ^ Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. World Health Organization. 2004. ISBN 92-4-159115-3.
- ^ http://whqlibdoc.who.int/unaids/2004/9241591153_eng.pdf
- ^ Chen, Kevin W.; Banducci, Annie N.; Guller, Leila; MacAtee, Richard J.; Lavelle, Anna; Daughters, Stacey B.; Lejuez, C.W. (2011). "An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program". Drug and Alcohol Dependence 118 (2-3): 92–9. doi:10.1016/j.drugalcdep.2011.03.003. PMID 21514751.
- ^ Praveen, KT; Law, F; O'Shea, J; Melichar, J (2012). "Opioid dependence". American family physician 86 (6): 565–6. PMID 23062049. edit
- ^ Vargas-Perez, H.; Ting-A-Kee, R.; Walton, C. H.; Hansen, D. M.; Razavi, R.; Clarke, L.; Bufalino, M. R.; Allison, D. W. et al. (2009). "Ventral Tegmental Area BDNF Induces an Opiate-Dependent-Like Reward State in Naive Rats". Science 324 (5935): 1732–34. doi:10.1126/science.1168501. PMC 2913611. PMID 19478142.
- ^ Laviolette, Steven R.; Van Der Kooy, Derek (2001). "GABAA receptors in the ventral tegmental area control bidirectional reward signalling between dopaminergic and non-dopaminergic neural motivational systems". European Journal of Neuroscience 13 (5): 1009–15. doi:10.1046/j.1460-9568.2001.01458.x. PMID 11264674.
- ^ Goeldner, Celia; Lutz, Pierre-Eric; Darcq, Emmanuel; Halter, Thomas; Clesse, Daniel; Ouagazzal, Abdel-Mouttalib; Kieffer, Brigitte L. (2011). "Impaired Emotional-Like Behavior and Serotonergic Function During Protracted Abstinence from Chronic Morphine". Biological Psychiatry 69 (3): 236–44. doi:10.1016/j.biopsych.2010.08.021. PMC 3014999. PMID 20947067.
- ^ Praveen, KT; Law, F; O'Shea, J; Melichar, J (2012). "Opioid dependence". American family physician 86 (6): 565–6. PMID 23062049. edit
- ^ Nicholls L, Bragaw L, Ruetsch C. (Feb 2010). "Opioid Dependence Treatment and guidelines". J Manag Care Pharm. 16 (1 Suppl B): S14–21. PMID 20146550.
- ^ - Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence - World Health Organization
- ^ Amy Maxmen (June 2012), “Tackling the US pain epidemic”. Nature News doi:10.1038/nature.2012.10766
- ^ a b c d Joseph, H; Stancliff, S; Langrod, J (2000). "Methadone maintenance treatment (MMT): A review of historical and clinical issues". The Mount Sinai journal of medicine, New York 67 (5–6): 347–64. PMID 11064485.
- ^ Connock, M; Juarez-Garcia, A; Jowett, S; Frew, E; Liu, Z; Taylor, RJ; Fry-Smith, A; Day, E et al. (2007). "Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation". Health technology assessment 11 (9): 1–171, iii–iv. PMID 17313907.
- ^ http-www.rcgp.org.uk-PDF-drug_meth%20guidance.pdf
- ^ Bell, J.R; Butler, B., Lawrence, A., Batey, R. & Salmelainen (2009). "Comparing overdose mortality associated with methadone and buprenorphine treatment". Drug and Alcohol Dependence 104: 73–7.
- ^ Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2011, Issue 4. PMID 21491383
- ^ Haasen, C.; Verthein, U.; Degkwitz, P.; Berger, J.; Krausz, M.; Naber, D. (2007). "Heroin-assisted treatment for opioid dependence: Randomised controlled trial". The British Journal of Psychiatry 191: 55–62. doi:10.1192/bjp.bp.106.026112. PMID 17602126.
- ^ http://relaunch.bundestag.de/bundestag/ausschuesse/a14/anhoerungen/113/stllg/ZIS.pdf[dead link]
- ^ Brewer, C; H Rezae, C Bailey (1988). "Opioid withdrawal and naltrexone induction in 48-72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique". The British Journal of Psychiatry 153 (3): 340–343. doi:10.1192/bjp.153.3.340. PMID 3250670.
- ^ Ling, W; L Amass, S Shoptaw, JJ Annon, M Hillhouse, D Babcock, G Brigham, J Harrer, M Reid, J Muir, B Buchan, D Orr, G Woody, J Krejci, D Ziedonis (2005). "A multi-center randomized trial of buprenorphine–naloxone versus clonidine for opioid, detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network". Addiction 100 (8): 1090–1100. doi:10.1111/j.1360-0443.2005.01154.x. PMID 16042639.
- ^ a b Herman, BH; F Vocci, P Bridge (1995). "The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal: Medication development issues for opiate addiction". Neuropsychopharmacology 13 (4): 269–293. doi:10.1016/0893-133X(95)00140-9. PMID 8747752.
- ^ Alper, KR; HS Lotsof, GMN Frenken, DJ Luciano, J Bastiaans (1999). "Treatment of Acute Opioid Withdrawal with Ibogaine". The American Journal of Addictions 8 (3): 234–243. doi:10.1080/105504999305848. PMID 10506904.
- ^ Morel LJ, Giros B, Daugé V (2009). "Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats". Neuropsychopharmacology 34 (11): 2469–76. doi:10.1038/npp.2009.70. PMID 19553915. Lay summary – PhysOrg.com (7 July 2009).
- ^ Raby, Wilfrid Noel; Carpenter, Kenneth M.; Rothenberg, Jami; Brooks, Adam C.; Jiang, Huiping; Sullivan, Maria; Bisaga, Adam; Comer, Sandra et al. (2009). "Intermittent Marijuana Use Is Associated with Improved Retention in Naltrexone Treatment for Opiate-Dependence". The American Journal on Addictions 18 (4): 301–8. doi:10.1080/10550490902927785. PMC 2753886. PMID 19444734.
- ^ Boyer, Edward W.; Kavita M. Babu, Jessica E. Adkins, Christopher R. McCurdy, John H. Halpern (28 June 2008). "Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)". Addiction 103 (6): 1048–1050. doi:10.1111/j.1360-0443.2008.02209.x. PMID 18482427.
- ^ Sobey, PW; Parran Tv, TV; Grey, SF; Adelman, CL; Yu, J (2003). "The use of tramadol for acute heroin withdrawal: a comparison to clonidine". Journal of addictive diseases 22 (4): 13–25. PMID 14723475.
- ^ Threlkeld, M; Parran, TV; Adelman, CA; Grey, SF; Yu, J; Yu, Jaehak (2006). "Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study". The American journal on addictions 15 (2): 186–91. doi:10.1080/10550490500528712. PMID 16595358.
- ^ Brigham, Ph.D., Gregory (August 2, 2003). "12-Step Participation as a Pathway to Recovery: The Maryhaven Experience and Implications for Treatment and Research". Treatment Research. PMC. Retrieved 11 June 2013.
- ^ Alexandre B. Laudet, Ph.D - PowerPoint PPT Presentation - 12-step attendance and involvement over 3 years on odds of sustained abstinence
- ^ Manning, V; Best D., Faulkner N., Titherington E., Morinan A., Keaney F., Gossop M., Strang J. (November 2012). "Does active referral by a doctor or 12-Step peer improve 12-Step meeting attendance? Results from a pilot randomised control trial.". Research study. NCBI Pubmed.gov. Retrieved 11 June 2013.
External links[edit]
- http://www.drugabuse.gov/infofacts/heroin.html
- http://www.licadd.com/drug-alcohol-info/heroin/
- http://www.opioids.net
- Opioid Dependence Treatment and guidelines
|
Opioids
|
|
Opium and
poppy straw
derivatives |
Crude opiate
extracts /
whole opium
products |
- B&O Supprettes
- Diascordium
- Dover's powder
- Kendal Black Drop
- Laudanum
- Mithridate
- Opium
- Paregoric
- Polish heroin (compote/kompot)
- Poppy straw
- Poppy tea
- Smoking opium
- Theriac
|
|
| Natural opiates |
Opium
alkaloids |
- Codeine
- Morphine
- Oripavine
- Pseudomorphine
- Thebaine
|
|
Alkaloid
salts mixtures |
- Pantopon
- Papaveretum (Omnopon)
|
|
|
Semisynthetics
including
Bentley
compounds |
Morphine
family |
- 2,4-Dinitrophenylmorphine
- 6-MDDM
- Azidomorphine
- Chlornaltrexamine
- Desocodeine
- Desomorphine
- Dihydromorphine
- Hydromorphinol
- Methyldesorphine
- N-Phenethylnormorphine
- RAM-378
|
|
3,6-diesters
of morphine |
- Acetylpropionylmorphine
- Diacetyldihydromorphine
- Dibenzoylmorphine
- Dipropanoylmorphine
- Heroin
- Nicomorphine
|
|
Codeine-dionine
family |
- 6-Monoacetylcodeine
- Benzylmorphine
- Codeine methylbromide
- Ethylmorphine
- Heterocodeine
- Isocodeine
- Myrophine
- Pholcodine
|
|
Morphinones
and morphols |
- 14-Cinnamoyloxycodeinone
- 14-Ethoxymetopon
- 14-Methoxymetopon
- 14-Phenylpropoxymetopon
- 3-Acetyloxymorphone
- 3,14-Diacetyloxymorphone
- 6-MDDM
- 7-Spiroindanyloxymorphone
- Acetylmorphone
- Codeinone
- Codoxime
- Conorfone
- Hydrocodone
- Hydromorphone
- IBNtxA
- Methyldihydromorphine
- Metopon
- Morphinone
- N-Phenethyl-14-ethoxymetopon
- Nalmexone
- Oxycodone
- Oxymorphol
- Oxymorphone
- Pentamorphone
- Semorphone
- Thebacon
|
|
| Morphides |
- α-Chlorocodide
- Chloromorphide
|
|
Dihydrocodeine
series |
- 14-Hydroxydihydrocodeine
- Acetyldihydrocodeine
- Dihydrocodeine
- Nicocodeine
- Nicodicodeine
|
|
Nitrogen
morphine
derivatives |
- Codeine-N-oxide
- Morphine-N-oxide
|
|
| Hydrazones |
|
|
Halogenated
morphine
derivatives |
|
|
|
Active opiate
metabolites |
- 6-Monoacetylmorphine
- Morphine-6-glucuronide
- Norcodeine
- Normorphine
|
|
|
| Morphinans |
- 3-Hydroxymorphinan
- Butorphanol
- Cyclorphan
- Cyprodime
- Dextrallorphan
- Drotebanol
- Ketorfanol
- Levallorphan
- Levomethorphan
- Levophenacylmorphan
- Levorphanol
- Nalbuphine
- Norlevorphanol
- Oxilorphan
- Phenomorphan
- Proxorphan
- Racemethorphan/Methorphan
- Racemorphanol/Morphanol
- Ro4-1539
- Sinomenine/Cocculine
- Xorphanol
|
|
| Benzomorphans |
- 8-CAC
- Alazocine
- Anazocine
- Bremazocine
- Butinazocine
- Carbazocine
- Cogazocine
- Dezocine
- Eptazocine
- Etazocine
- Ethylketazocine
- Fluorophen
- Ibazocine
- Ketazocine
- Metazocine
- Moxazocine
- Pentazocine
- Phenazocine
- Tonazocine
- Volazocine
- Zenazocine
|
|
| 4-Phenylpiperidines |
Pethidines
(Meperidines) |
- 4-Fluoropethidine
- Allylnorpethidine
- Anileridine
- Benzethidine
- Carperidine
- Difenoxin
- Diphenoxylate
- Etoxeridine (Carbetidine)
- Furethidine
- Hydroxypethidine (Bemidone)
- Morpheridine
- Oxpheneridine (Carbamethidine)
- Pethidine (Meperidine)
- Pethidine intermediate A
- Pethidine intermediate B (Norpethidine)
- Pethidine intermediate C (Pethidinic Acid)
- Pheneridine
- Phenoperidine
- Piminodine
- Properidine (Ipropethidine)
- Sameridine
|
|
| Prodines |
- Allylprodine
- Meprodine (α-meprodine / β-meprodine)
- MPPP (Desmethylprodine)
- PEPAP
- Prodine (α-prodine / β-prodine)
- Prosidol
- Trimeperidine (Promedol)
|
|
| Ketobemidones |
- Acetoxyketobemidone
- Droxypropine
- Ketobemidone
- Methylketobemidone
- Propylketobemidone
|
|
| Others |
- Alvimopan
- Loperamide
- Picenadol
|
|
|
Open chain
opioids |
| Amidones |
- Dipipanone
- Isomethadone
- Levomethadone
- Methadone
- Normethadone
- Norpipanone
- Phenadoxone (Heptazone)
|
|
| Methadols |
- Acetylmethadol
- Alphacetylmethadol
- Alphamethadol
- Betacetylmethadol
- Betamethadol
- Dimepheptanol (methadol)
- Isomethadol
- Levacetylmethadol
- Noracymethadol
|
|
| Moramides |
- Desmethylmoramide
- Dextromoramide
- Levomoramide
- Moramide/Racemoramide
|
|
| Thiambutenes |
- Diethylthiambutene
- Dimethylthiambutene
- Ethylmethylthiambutene
- Piperidylthiambutene
- Pyrrolidinylthiambutene
- Tipepidine
|
|
| Phenalkoxams |
- Dextropropoxyphene
- Dimenoxadol
- Dioxaphetyl butyrate
- Levopropoxyphene
- Norpropoxyphene
|
|
| Ampromides |
- Diampromide
- Phenampromide
- Propiram
|
|
| Others |
- Alimadol
- IC-26
- Isoaminile
- Lefetamine
- R-4066
|
|
|
| Anilidopiperidines |
- 3-Allylfentanyl
- 3-Methylfentanyl
- 3-Methylthiofentanyl
- 4-Phenylfentanyl
- α-methylacetylfentanyl
- α-Methylfentanyl
- α-methylthiofentanyl
- β-hydroxyfentanyl
- β-hydroxythiofentanyl
- β-methylfentanyl
- Alfentanil
- Brifentanil
- Carfentanil
- Fentanyl
- Lofentanil
- Mirfentanil
- Ocfentanil
- Ohmefentanyl
- Parafluorofentanyl
- Phenaridine
- Remifentanil
- Sufentanil
- Thiofentanyl
- Trefentanil
|
|
Oripavine
derivatives |
- 7-PET
- Acetorphine
- Alletorphine
- BU-48
- Buprenorphine
- Cyprenorphine
- Dihydroetorphine
- Etorphine
- Homprenorphine
- Norbuprenorphine
|
|
| Phenazepanes |
- Ethoheptazine
- Meptazinol
- Metethoheptazine
- Metheptazine
- Proheptazine
|
|
| Pirinitramides |
|
|
| Benzimidazoles |
|
|
| Indoles |
- 18-MC
- 7-Hydroxymitragynine
- Akuammine
- Eseroline
- Hodgkinsine
- Ibogaine
- Mitragynine
- Noribogaine
- Pericine
|
|
Diphenylmethyl-
piperazines |
- BW373U86
- DPI-221
- DPI-287
- DPI-3290
- SNC-80
|
|
| Opioid peptides |
- Adrenorphin
- Amidorphin
- Biphalin
- Casokefamide
- Casomorphin
- Cytochrophin
- DADLE
- DAMGO
- Deltorphin
- Dermorphin
- Dynorphin
- Endomorphin
- Endorphins
- Enkephalin
- Frakefamide
- Gliadorphin
- Hemorphin
- Leumorphin
- Metkefamide
- Morphiceptin
- Neoendorphin
- Nociceptin
- Octreotide
- Opiorphin
- Rubiscolin
- Spinorphin
- TRIMU 5
- Tynorphin
- Valorphin
|
|
| Others |
- AD-1211
- AH-7921
- Azaprocin
- BRL-52537
- Bromadol
- Bromadoline
- C-8813
- Ciprefadol
- Ciramadol
- Doxpicomine
- Enadoline
- Ethanol
- Faxeladol
- GR-89696
- Herkinorin
- ICI-199,441
- ICI-204,448
- J-113,397
- JTC-801
- LPK-26
- MCOPPB
- Metofoline
- MT-45
- N-Desmethylclozapine
- NNC 63-0532
- Nortilidine
- O-Desmethyltramadol
- Phenadone
- Phencyclidine
- Prodilidine
- Profadol
- Ro64-6198
- Salvinorin A
- SB-612,111
- SC-17599
- RWJ-394,674
- TAN-67
- Tapentadol
- Tifluadom
- Tilidine
- Tramadol
- Trimebutine
- U-50,488
- U-69,593
- Viminol
- W-18
|
|
Opioid
antagonists &
inverse agonists |
- 5'-Guanidinonaltrindole
- Alvimopan
- Chlornaltrexamine
- Chloroxymorphamine
- Conorfone
- Cyclazocine
- Cyprodime
- Diacetylnalorphine
- Difenamizole
- Diprenorphine (M5050)
- Gemazocine
- JDTic
- Levallorphan
- LY-255,582
- Methylnaltrexone
- Nalbuphine
- Naldemedine
- Nalmefene
- Nalmexone
- Nalorphine
- Nalorphine dinicotinate
- Naloxazone
- Naloxegol
- Naloxonazine
- Naloxone
- Naltrexol-d4
- Naltrexone
- Naltriben
- Naltrindole
- Norbinaltorphimine
- Oxilorphan
- Quadazocine
- Samidorphan
- Tonazocine
- Zenazocine
|
|
Uncategorized
opioids |
- Anilopam
- Asimadoline
- Axomadol
- FE 200665
- Fedotozine
- Nalfurafine
- Nalorphine
- Nalorphine dinicotinate
- SoRI-9409
|
|
|
|
|
|
Psychoactive substance-related disorder (F10–F19, 291–292; 303–305)
|
|
| General |
- SID
- Substance intoxication / Drug overdose
- Withdrawal
- Substance-induced psychosis
- SUD
- Substance abuse
- Physical dependence / Substance dependence
|
|
| Alcohol |
|
SID
|
|
Diseases
|
|
Neurological
disorders
|
- Alcoholic hallucinosis
- Alcohol withdrawal
- Fetal alcohol spectrum disorder (FASD)
- Fetal alcohol syndrome (FAS)
- Korsakoff's syndrome
- Wernicke–Korsakoff syndrome
- Wernicke's encephalopathy
|
|
|
Digestive
system
|
- Alcohol flush reaction
- Alcoholic hepatitis
- Alcoholic liver disease
|
|
|
Nervous
system
|
- Alcohol dementia
- Alcoholic hallucinosis
- Hangover
|
|
|
Cardiovascular
system
|
|
|
|
|
|
SUD
|
- Alcoholism (Alcohol dependence syndrome)
- Alcohol abuse
|
|
|
| Opioids |
|
|
| Cannabis |
- SID
- Short-term effects of cannabis
- Cannabis withdrawal
- SUD
|
|
Sedative /
hypnotic |
- benzodiazepine: SID
- Benzodiazepine overdose
- Benzodiazepine withdrawal
- SUD
- Benzodiazepine misuse
- Benzodiazepine dependence
- barbiturate: SID
- SUD
|
|
| Cocaine |
|
|
| Stimulants |
- SID
- SUD
- Health effects of caffeine
- Caffeine-induced sleep disorder
|
|
| Hallucinogen |
- SID
- Hallucinogen persisting perception disorder
|
|
| Tobacco |
- SID
- Nicotine poisoning
- Nicotine withdrawal
|
|
Volatile
solvent |
- Inhalant abuse: Toluene toxicity
|
|
| Multiple |
|
|
|
|
|
dsrd (o, p, m, p, a, d, s), sysi/epon, spvo
|
proc (eval/thrp), drug (N5A/5B/5C/6A/6B/6D)
|
|
|
|
